Short answer
BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on August 6, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 unaudited results for quarter ended June 30, 2026.
BIOLIFE SOLUTIONS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 unaudited results for quarter ended June 30, 2026
- Operational highlights announced August 6, 2026
- Financial figures and management commentary contained in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $28.5M, up 21% year over year, with adjusted EBITDA $7.4M and 26% margin
- GAAP gross margin 64%, down from 65%, while adjusted gross margin declined to 65% from 66%
- GAAP net income $45.1M included a $42.4M non-cash tax benefit, making adjusted net income $4.2M more representative
- Repligen agreed to acquire BioLife for approximately $1.5B enterprise value, including $11.25 cash and 0.1442 Repligen shares per BioLife share
- Transaction expected to close in Q4 2026, subject to shareholder and regulatory approvals, after which BioLife will cease public trading
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOLIFE SOLUTIONS INC 8-K filings
Get the next BLFS 8-K as it lands
Follow BLFS for push alerts, or ask the research agent what this filing means.